retatrutide obesity trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple hormone receptor agonist retatrutide
Description
The program also integrates seamlessly with our other wellness services including Hormone Replacement Therapy, Peptide Therapy, and IV Vitamin Therapy for patients whose weight challenges have additional hormonal or nutritional contributing factors
If youre struggling with a chronic condition such as heart disease, kidney dysfunction, fatty liver, or inflammatory bowel disease, GLP-1 medications may offer more than metabolic supportthey could help reduce inflammation and protect your long-term health
Our results demonstrated that GLP-1-SSM markedly reduced the inflammation and partially attenuated the diarrheal phenotype in DSS colitis mice
2006;83(2):461S5S
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Aronne is a world-renowned physician, researcher, professor, and leading expert in weight management and GLP-1 medications
